{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:02:31Z","timestamp":1781272951116,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2024-MS-226"],"award-info":[{"award-number":["2024-MS-226"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20224ACB216016"],"award-info":[{"award-number":["20224ACB216016"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232ACB206060"],"award-info":[{"award-number":["20232ACB206060"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20242BAB23092"],"award-info":[{"award-number":["20242BAB23092"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22367011"],"award-info":[{"award-number":["22367011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22367012"],"award-info":[{"award-number":["22367012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118856","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:08:52Z","timestamp":1775840932000},"page":"118856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel bis-aryl urea-linked triazine derivatives as dual PI3K\/mTOR inhibitors via scaffold hopping strategy and biological activity evaluations"],"prefix":"10.1016","volume":"311","author":[{"given":"Zhenjie","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujue","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9999-9899","authenticated-orcid":false,"given":"Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengwu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118856_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118856_bib2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1053\/j.gastro.2020.10.030","article-title":"Cancer screening during the coronavirus Disease-2019 pandemic: a perspective from the national cancer institute's PROSPR consortium COMMENT","volume":"160","author":"Corley","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.118856_bib3","first-page":"2053","article-title":"The research progress of PROTACs for breast cancer treatment","volume":"55","author":"Xie","year":"2020","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.ejmech.2026.118856_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12931-024-03045-0","article-title":"Cromolyn sodium reduces LPS-induced pulmonary fibrosis by inhibiting the EMT process enhanced by MC-derived IL-13","volume":"26","author":"Tan","year":"2025","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2026.118856_bib5","article-title":"Exploring the efficacy and molecular mechanism of Danhong injection comprehensively in the treatment of idiopathic pulmonary fibrosis by combining meta-analysis, network pharmacology, and molecular docking methods","volume":"103","author":"Wu","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.ejmech.2026.118856_bib6","first-page":"94","article-title":"Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K\/AKT\/mTOR and EMT pathways","volume":"16","author":"Chen","year":"2024","journal-title":"Chin. Herb. Med."},{"key":"10.1016\/j.ejmech.2026.118856_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113537","article-title":"XS-2, a novel potent dual PI3K\/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer","volume":"155","author":"Xu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.118856_bib8","first-page":"548","article-title":"Compound Danshen Tablets ameliorate myocardial ischemia\/reperfusion injury-induced ventricular remodeling by regulating autophagy via AMPK\/mTOR signaling pathway","volume":"17","author":"Li","year":"2025","journal-title":"Chin. Herb. Med."},{"key":"10.1016\/j.ejmech.2026.118856_bib9","first-page":"322","article-title":"Enhancement of apoptosis in HCT116 and HepG2 cells by Coix lacryma-jobivar. Lacryma-jobiseed extract in combination with sorafenib","volume":"17","author":"Parhira","year":"2025","journal-title":"Chin. Herb. Med."},{"key":"10.1016\/j.ejmech.2026.118856_bib10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41416-025-03035-z","article-title":"Multi-node inhibition targeting mTORC1, mTORC2 and PI3K\u03b1 potently inhibits the PI3K\/AKT\/mTOR pathway in endometrial and breast cancer models","volume":"133","author":"Tyrakis","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118856_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106779","article-title":"Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer","volume":"140","author":"Yang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib12","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.3390\/molecules30112347","article-title":"A PI3K inhibitor with low cardiotoxicity and its synergistic inhibitory effect with gilteritinib in Acute Myelogenous Leukemia (AML) cells","volume":"30","author":"Wu","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118856_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/0008-5472.CAN-11-1515","article-title":"Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition","volume":"72","author":"Hoeflich","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118856_bib14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-11-1021","article-title":"Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations","volume":"11","author":"Brachmann","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118856_bib15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ejca.2008.12.007","article-title":"Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor","volume":"45","author":"Kong","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118856_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108011","article-title":"Current developments in PI3K-based anticancer agents: designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight","volume":"154","author":"Ashadul Sk","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12967-022-03462-z","article-title":"Inhibition of autophagy by chloroquine prevents resistance to PI3K\/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models","volume":"20","author":"Cocco","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.118856_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ddstr.2009.12.001","article-title":"mTOR mediated anti-cancer drug discovery","volume":"6","author":"Liu","year":"2009","journal-title":"Drug Discov. Today Ther. Strat."},{"key":"10.1016\/j.ejmech.2026.118856_bib19","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1021\/jm400194n","article-title":"Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the Mammalian target of Rapamycin (mTOR)","volume":"56","author":"Estrada","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib20","doi-asserted-by":"crossref","first-page":"82027","DOI":"10.18632\/oncotarget.18303","article-title":"ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo","volume":"8","author":"Yin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.118856_bib21","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/cells13121064","article-title":"Combination therapy approach to overcome the resistance to PI3K pathway inhibitors in gynecological cancers","volume":"13","author":"Ibanez","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.118856_bib22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1517\/17460441.2013.800479","article-title":"Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment","volume":"8","author":"Lv","year":"2013","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118856_bib23","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.18632\/oncotarget.12742","article-title":"Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.118856_bib24","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1021\/acs.jmedchem.5b02041","article-title":"Delineation of polypharmacology across the human structural kinome using a functional site interaction fingerprint approach","volume":"59","author":"Zhao","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17460441.2017.1280024","article-title":"Computational polypharmacology: a new paradigm for drug discovery","volume":"12","author":"Chaudhari","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118856_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115543","article-title":"Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K\/mTOR dual inhibitor for the treatment of acute myeloid leukemia","volume":"258","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1567201820666230504145614","article-title":"Therapeutic approaches of dual-targeted nanomedicines for tumor multi-drug resistance","volume":"21","author":"Han","year":"2024","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejmech.2026.118856_bib28","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1002\/med.22057","article-title":"Rethinking therapeutic strategies of dual-target drugs: an update on pharmacological small-molecule compounds in cancer","volume":"44","author":"Yang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118856_bib29","article-title":"Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy","volume":"1878","author":"Ye","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2026.118856_bib30","doi-asserted-by":"crossref","first-page":"15220","DOI":"10.1021\/acs.jmedchem.4c00837","article-title":"Discovery of novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based derivatives as potent CDK\/HDAC dual inhibitors for the treatment of refractory solid tumors and hematological malignancies","volume":"67","author":"Saidahmatov","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib31","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.1158\/0008-5472.CAN-07-2154","article-title":"A dual phosphoinositide-3-kinase \u03b1\/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma","volume":"67","author":"Fan","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118856_bib32","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1021\/jm2009327","article-title":"Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-Kinase (PI3K)\/Mammalian target of Rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer","volume":"54","author":"Sutherlin","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib33","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","article-title":"Antitumor efficacy of PKI-587, a highly potent dual PI3K\/mTOR Kinase inhibitor","volume":"17","author":"Mallon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118856_bib34","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1158\/0008-5472.CAN-06-4615","article-title":"Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases","volume":"67","author":"Raynaud","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118856_bib35","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.bmcl.2007.02.032","article-title":"Synthesis and biological evaluation of pyrido 3\u2032,2':4,5 furo 3,2-d pyrimidine derivatives as novel PI3 kinase p110\u03b1 inhibitors","volume":"17","author":"Hayakawa","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118856_bib36","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-14-1306","article-title":"First-in-Human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118856_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112637","article-title":"Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K\/mTOR inhibitors","volume":"204","author":"Wu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/jm501026z","article-title":"Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-Kinase-Related kinase (PIKK) inhibitors: importance of the morpholine ring","volume":"58","author":"Andrs","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112391","article-title":"Targeting mTOR for fighting diseases: a revisited review of mTOR inhibitors","volume":"199","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118856_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e13075","article-title":"Results of the safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA 1\/2 positive HER2 negative breast cancer","volume":"40","author":"Phadke","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118856_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5109","article-title":"A phase 1\/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Heath","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118856_bib42","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2015.63.9179","article-title":"Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with Estrogen receptor-positive breast cancer","volume":"34","author":"Schmid","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118856_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.160629","article-title":"A spatial confinement biological heterogeneous cascade nanozyme composite hydrogel combined with nitric oxide gas therapy for enhanced treatment of psoriasis and diabetic wound","volume":"507","author":"Zhang","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejmech.2026.118856_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-025-03627-w","article-title":"Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib","volume":"45","author":"Yu","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:43:48Z","timestamp":1781271828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"alternative-id":["S0223523426003016"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118856","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel bis-aryl urea-linked triazine derivatives as dual PI3K\/mTOR inhibitors via scaffold hopping strategy and biological activity evaluations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118856"}}